IGM Biosciences, Inc. (IGMS)

10,07 +0,64 (+6,79%) Alla chiusura: 04:00PM EDT

IGM Biosciences, Inc.

325 East Middlefield Road
Mountain View, CA 94043
United States
650 965 7873
https://igmbio.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 224

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Fred M. Schwarzer J.D.	CEO, President & Director	1M	N/D	1953
Dr. Bruce A. Keyt Ph.D.	Chief Scientific Officer	713,78k	N/D	1953
Dr. Chris H. Takimoto FACP, M.D., Ph.D.	Chief Medical Officer	705,39k	N/D	1959
Mr. Misbah Tahir	Chief Financial Officer	957,6k	N/D	1975
Mr. TS Harigopal	Senior Vice President of Group Operations	N/D	N/D	N/D
Mr. Paul C. Graffagnino	Senior Vice President of Legal Affairs	N/D	N/D	N/D
Ms. Suzette Tauber	Chief Human Resources Officer	N/D	N/D	1964
Dr. Angus M. Sinclair Ph.D.	Senior Vice President of Immuno-Oncology	N/D	N/D	N/D
Dr. Lisa L. Decker Ph.D.	Chief Business Officer	528,18k	N/D	1970
Dr. Marvin S. Peterson Ph.D.	Executive Vice President of Process Development & Manufacturing	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Governance aziendale

L'ISS Governance QualityScore di IGM Biosciences, Inc. al 1 maggio 2024 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.